KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $4.5 million.

  • Aquestive Therapeutics' Other Operating Expenses rose 1.56% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 4.39%. This contributed to the annual value of $17.9 million for FY2024, which is 14.20% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Other Operating Expenses of $4.5 million as of Q3 2025, which was down 1.21% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Other Operating Expenses peaked at $6.6 million during Q2 2023, and registered a low of $2.8 million during Q1 2021.
  • Its 3-year average for Other Operating Expenses is $4.7 million, with a median of $4.5 million in 2024.
  • As far as peak fluctuations go, Aquestive Therapeutics' Other Operating Expenses skyrocketed by 57.61% in 2022, and later plummeted by 31.60% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Other Operating Expenses (Quarterly) stood at $3.4 million in 2021, then skyrocketed by 57.61% to $5.3 million in 2022, then decreased by 11.80% to $4.7 million in 2023, then fell by 3.40% to $4.5 million in 2024, then rose by 1.56% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.6 million for Q2 2025, and $3.7 million during Q1 2025.